Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial—PaCa-DD-041 (Eudra-CT 2009-011968-11)
ConclusionBased on these limited patient numbers, it was possible to show that this trial design is feasible and that the neoadjuvant therapy regime was well tolerated. FDG-PET/CT may be a reliable method to evaluate response to the combined therapy. In contrast, when evaluating the response using mean ADC, DW-MRI did not show conclusive results.
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Borderline Tumor | Cancer | Cancer & Oncology | Chemotherapy | CT Scan | MRI Scan | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | PET Scan | Statistics | Study